Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77.21 USD | -0.13% | +7.90% | +0.06% |
Jul. 01 | Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell Midcap Growth Index | CI |
Jul. 01 | Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000 Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.06% | 12.17B | |
+22.15% | 46.56B | |
+45.94% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
-8.52% | 11.14B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024